Deep Pharmacy Intelligence will be released “Landscape of Advanced Technology Companies in the Pharmaceutical Industry (Q2 2021)”.

Artificial Intelligence (II) is the driving force behind the current digitalisation and pharmaceutical research.

– Dr. Andrew Buvalo

LONDON, United States, August 10, 2021 / – Deep Pharmacy Information Releases New Report “Landscape of Advanced Technology Companies in the Pharmaceutical Industry (Q2 2021)”, a new series of market studies. On the technological ecology in the pharmaceutical industry. To our knowledge, this is their role in the initial strategic evaluation of such companies and in shaping drug discovery and clinical research.

This report highlights 145 leading technology companies in the following categories.

‘Big Tech’ corporations;
– R&D platform providers driven by artificial intelligence (II);
– Large data providers
– Quantum Computing Companies
– Automated laboratory developers, and laboratory automation suppliers
– Other high-tech services (support services)

The report describes the ecology and provides insights into key trends, strategic R&D collaboration, investments, technology application case studies and much more. Each category is discussed separately, giving examples of companies and technologies.

The report focuses on “big technology” players entering the pharmaceutical industry, highlighting high market activity, and business partnerships and investments.

Finally, the emergence of new types of business models, AI-drug-Candid-as-a-service, blockchain-based federal education, remote laboratories and testing as a service, computation, and ‘super-platforms’.

The main purpose of this report is to identify technological innovations into the pharmaceutical industry, and its impact on the industry as a whole. The insights from the report will be invaluable to corporate decision makers, technology scouts, high-tech investors, and other stakeholders in the pharmaceutical business.

Dip Pharmaceutical Intelligence Director Dr. Andrew Buvalo said: “Artificial Intelligence (II) is the driving force behind the current digitalisation and pharmaceutical research. However, the AI ​​is not worth it in itself, it must be relied upon for big data, computational infrastructure, automated experimental research, data exchange protocols and much more.

“As pharmaceutical companies become more accepting of AI, they will be dependent on all other technologies, enabling data-based drug discovery and pharmaceutical industry 4.0. In our study, we provide insights into where the industry is moving with technologies and where partnerships are emerging. ”, Andrew continues.

Access Report Reduction “Landscape of Advanced Technology Companies in the Pharmaceutical Industry (Q2 2021)” at:

Thinking about deep pharmacy
Deep Pharmacy Intelligence Deep Knowledge Analysis Pharmacy Division and BPT Analytics (BiopharmaTrend) is a joint report on powerful data mining and visual systems, interactive analysis dashboards and in-depth technical insights, business knowledge, competitive analysis, industrial benchmarking and strategic guidance. , AI in Drug Discovery, Emerging Medical Goals and Pharmaceuticals, New Treatments and Technologies, Promising Beginnings, and more in the pharmaceutical industry.

Analysis of in-depth knowledge
DeepTech-based agency that provides advanced analytics on DeepTech and the cross-technology industry using advanced multi-dimensional frameworks and algorithms that combine in-depth market knowledge, practical forecasts and metrics with hundreds of unique-designed and especially weighted metrics and metrics is it. Real Estate Benchmarking.

About BPT Analytics (BiopharmaTrend)
BiopharmaTrend is a leading provider of analytics, marketing expertise, articles, comments, opinions and interviews on the pharmaceutical and healthcare industries. They are currently developing an analytics platform that maps companies, competitors, key people, deals, mediation cycles, news, trends, research articles, proprietary rights and other relevant information into industry knowledge graphs. The company is designed to serve as a research engine to market strategic and strategic insights for marketers, investors, business developers, entrepreneurs, and the pharmaceutical industry and healthcare. BiopharmaTrend information about all the components of the industry knowledge is manually adjusted using the Parser engine and several API integrations as well as the company’s internal workflow.

About the Deep Knowledge Group
The Deep Knowledge Group is a global coalition of business and non-profit organizations focused on the same integration of Diptech and Border Technologies (II, Longevity, Medtech, Fintech, Govtek), with long-term implementation of information-driven investment-tech solutions. A strategic focus on AI in health care, longevity and real health, and with the aim of achieving a positive impact by supporting progressive technologies for the benefit of mankind through scientific research, investment, entrepreneurship, analysis and philanthropy.

For press and media questions, please contact

Dr. Andrew Buvalo
Deep Pharma Intelligence
Visit us on social media:


Leave a Comment